Name: Latest research reports of Aurobindo Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 3
Author: BOB Capital Markets Ltd.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer

1085.0000 -14.10 (-1.28%)

NSE Oct 24, 2025 15:31 PM

Volume: 761.5K

Aurobindo Pharma Ltd.

13 Feb 2024

1085.00

-1.28%

Aurobindo Pharma (HOLD): Strong margin uptick

Hold: Aurobindo Pharma Ltd.

Target

BOB Capital Markets Ltd.

Q3 EBITDA/PAT surged 68%/90% YoY led by growth in US/EM revenue and ~700bps jump in operating margin

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1081.3